Biotechs raised $1.1 billion via 24 follow-ons in 2Q12, bringing the total for the first half to 59 follow-ons that raised $3.2 billion. This compares to $1.3 billion raised in 25 deals in 2Q11, and $3 billion from 54 deals in 1H11. The 2Q12 group was up a median of 1%. The market value for Arena Pharmaceuticals Inc. (NASDAQ:ARNA) is up 81% since its follow-on, which priced on the heels of an FDA panel supporting approval of obesity candidate Belviq lorcaserin. FDA approved Belviq on June 27. (A) Follow-ons of units consisting of stock and warrants are excluded from the post-money and percentage change calculations because the price per share was not available; (B) Totals for post-money and June 29 market values exclude unit deals and acquired companies; (C) Median percentage change; $M; Source: BCIQ: BioCentury Online Intelligence

Company

Date

Raised

Post-$

6/29 mcap

% chg

Trimel Pharmaceuticals Corp. (TSX:TRL)

6/29/12

$12.9

NA

$146.0

NA

Omeros Corp. (NASDAQ:OMER)

6/27/12

$30.0

$260.1

$253.8

-2%

Coronado Biosciences Inc. (NASDAQ:CNDO)

6/22/12

$28.8

$121.9

$123.1

1%

AspenBio Pharma Inc. (NASDAQ:APPY)

6/20/12

$12.2

$15.4

$14.5

-6%

Cytokinetics Inc. (NASDAQ:CYTK)

6/20/12

$42.5

$101.4

$85.4

-16%

GenMark Diagnostics Inc. (NASDAQ:GNMK)

6/20/12

$42.0

$130.8

$135.1

3%

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)

6/14/12

$50.2

$368.4

$370.6

1%

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

5/31/12

$248.9

$4,678.3

$4,836.0

3%

Trovagene Inc. (NASDAQ:TROV) (A)

5/30/12

$10.6

NA

$53.9

NA

Delcath Systems Inc. (NASDAQ:DCTH) (A)

5/25/12

$23.0

NA

$108.1

NA

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) (A)

5/24/12

$4.8

NA

$16.3

NA

Arena Pharmaceuticals Inc. (NASDAQ:ARNA)

5/16/12

$69.6

$1,084.3

$1,967.6

81%

Prolor Biotech Inc. (NYSE-M:PBTH; Tel Aviv:PBTH)

5/11/12

$37.4

$311.4

$312.0

0%

Dynavax Technologies Corp. (NASDAQ:DVAX)

5/9/12

$74.4

$740.1

$752.2

2%

Merus Labs International Inc. (TSX:MSL; NASDAQ:MSLI)

5/4/12

$10.0

$54.2

$48.6

-10%

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)

5/4/12

$51.8

$296.1

$312.6

6%

PhotoMedex Inc. (NASDAQ:PHMD; Tel Aviv:PHMD)

4/27/12

$27.6

$289.0

$265.8

-8%

ReNeuron Group plc (LSE:RENE)

4/27/12

$9.9

$50.4

$45.8

-9%

Transcept Pharmaceuticals Inc. (NASDAQ:TSPT)

4/26/12

$40.5

$166.6

$114.9

-31%

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)

4/12/12

$67.3

$314.3

$518.3

65%

ArQule Inc. (NASDAQ:ARQL)

4/11/12

$60.0

$453.0

$368.9

-19%

Galena Biopharma Inc. (NASDAQ:GALE)

4/5/12

$14.6

$90.7

$108.3

19%

Clovis Oncology Inc. (NASDAQ:CLVS)

4/3/12

$75.0

$522.5

$566.5

8%

Derma Sciences Inc. (NASDAQ:DSCI)

4/2/12

$19.7

$118.1

$121.8

3%

2Q12 total (24 deals) (B)

$1,063.4

$10,167.1

$11,321.9

1% (C)

1Q12 total (35 deals) (B)

$2,146.8

$14,705.9

$17,784.9

10% (C)

1H12 total (59 deals) (B)

$3,210.2

$24,873.0

$29,106.8

2% (C)